RT @ElizSMcKenna: #AACRsarcoma22 starts tonight! ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeut…
RT @ElizSMcKenna: #AACRsarcoma22 starts tonight! ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeut…
RT @ElizSMcKenna: #AACRsarcoma22 starts tonight! ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeut…
RT @ElizSMcKenna: #AACRsarcoma22 starts tonight! ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeut…
RT @ElizSMcKenna: #AACRsarcoma22 starts tonight! ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeut…
RT @ElizSMcKenna: #AACRsarcoma22 starts tonight! ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeut…
#AACRsarcoma22 starts tonight! ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with #RareCancers @horak_p @StefanFrohling @DKFZ @NCT_HD @TMO_Heidelberg @uniklinik_hd @DKTK_ @NCT_UCC_DD http
RT @ElizSMcKenna: At the #AACR22 session on Development of Cancer Therapies for Ultra-Rare Indications? ICYMI in @CD_AACR: Comprehensive Ge…
RT @ElizSMcKenna: At the #AACR22 session on Development of Cancer Therapies for Ultra-Rare Indications? ICYMI in @CD_AACR: Comprehensive Ge…
RT @ElizSMcKenna: At the #AACR22 session on Development of Cancer Therapies for Ultra-Rare Indications? ICYMI in @CD_AACR: Comprehensive Ge…
RT @ElizSMcKenna: At the #AACR22 session on Development of Cancer Therapies for Ultra-Rare Indications? ICYMI in @CD_AACR: Comprehensive Ge…
RT @ElizSMcKenna: At the #AACR22 session on Development of Cancer Therapies for Ultra-Rare Indications? ICYMI in @CD_AACR: Comprehensive Ge…
RT @ElizSMcKenna: At the #AACR22 session on Development of Cancer Therapies for Ultra-Rare Indications? ICYMI in @CD_AACR: Comprehensive Ge…
At the #AACR22 session on Development of Cancer Therapies for Ultra-Rare Indications? ICYMI in @CD_AACR: Comprehensive Genomic & Transcriptomic Analysis for Guiding Therapeutic Decisions in #RareCancers @DKFZ @NCT_HD @TMO_Heidelberg @DKTK_ @NCT_UCC_DD
RT @aftimosp: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers https://t.c…
RT @aftimosp: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers https://t.c…
RT @aftimosp: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers https://t.c…
RT @aftimosp: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers https://t.c…
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers https://t.co/eVmrr9OE2P @OncoAlert #PrecisionMedicine
RT @ElizSMcKenna: ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with #…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with #…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with #…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with #…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with #…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with #…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with #…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with #…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with #…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with #…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with #…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with #…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with #…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with #…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with #…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with #…
ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with #RareCancers @horak_p @StefanFrohling @DKFZ @NCT_HD @TMO_Heidelberg @uniklinik_hd @DKTK_ @NCT_UCC_DD #RareDisease #RareDiseaseDay https:
RT @VivekSubbiah: # 20 b Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers…
RT @VivekSubbiah: # 20 b Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers…
RT @VivekSubbiah: # 20 b Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers…
RT @VivekSubbiah: # 20 b Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers…
RT @VivekSubbiah: # 20 b Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers…
RT @VivekSubbiah: # 20 b Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers…
RT @VivekSubbiah: # 20 b Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers…
# 20 b Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers @CD_AACR @ElizSMcKenna https://t.co/E0uxaJqnoJ
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers @CD_AACR @SWOG @DavendraSohal @kharofaJ https://t.co/vlsrm5zo5h
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
Thanks for sharing and many congratulations on this work, @StefanFrohling, @PeterHorak_MD and everyone involved.
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
Whole-genome/exome and RNA sequencing for guided therapeutic decisions in rare cancer! Truly bespoke medicine! Congratulations to @PeterHorak_MD, @StefanFrohling, Hanno Glimm, and the entire team!
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @Mom_enji: Wonderful paper! so great to see real-life clinical applications of broad sequencing, especially in these often neglected pop…
Wonderful paper! so great to see real-life clinical applications of broad sequencing, especially in these often neglected populations!
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @StefanFrohling: Please read in the new issue of @CD_AACR about the experience of @NCT_HD and @dktk with the clinical use of whole-genom…
RT @ElizSMcKenna: Watching the Rare Cancers session at #ESMO21? ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for G…
RT @ElizSMcKenna: Watching the Rare Cancers session at #ESMO21? ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for G…
RT @ElizSMcKenna: Watching the Rare Cancers session at #ESMO21? ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for G…
RT @ElizSMcKenna: Watching the Rare Cancers session at #ESMO21? ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for G…
RT @ElizSMcKenna: Watching the Rare Cancers session at #ESMO21? ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for G…
RT @ElizSMcKenna: Watching the Rare Cancers session at #ESMO21? ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for G…
RT @ElizSMcKenna: Watching the Rare Cancers session at #ESMO21? ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for G…
RT @ElizSMcKenna: Watching the Rare Cancers session at #ESMO21? ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for G…
RT @ElizSMcKenna: Watching the Rare Cancers session at #ESMO21? ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for G…
Watching the Rare Cancers session at #ESMO21? ICYMI in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with #RareCancers @horak_p @StefanFrohling @DKFZ @NCT_HD @TMO_Heidelberg @uniklinik_hd @DKTK_
@SBAmin I dont disagree with the authors' conclusion re: WGS being routine. Would have been great to see an example after the biopsy of 1st WGS they applied a different treatment and changed the tumor progression such as this paper: https://t.co/BkhI7zy2v5